Multiple Myeloma
Clinical development program expanded for Revimid
Published in Blood Weekly, August 8th, 2002
Celgene Corporation (CELG) announced the initiation of five additional trials of Revimid (CC-5013) in hematological and solid tumor cancers. The trials, conducted in partnership with the Comprehensive Cancer Center of Wake Forest University, the National Cancer Institute (NCI), the Dana-Farber Cancer Institute at Harvard University and the Arkansas Cancer Research Center, will evaluate the pharmacology, safety, and efficacy of Revimid as a treatment of multiple myeloma and all types of solid tumor cancers.
"Based on the antitumor activity that Revimid has demonstrated in preclinical and clinical studies, we believe it has significant potential in treating hematological...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2002-08-08)
More Articles from Blood Weekly
- Hematology
Novel dendritic cell subset found in mice - Stem Cell Transplantation
Excess iron could heighten mortality risk - Anemia
Low hemoglobin means high risk for mobility problems in elderly women - Lymphoma
Gene profiles predict survival - Stem Cell Transplantation
Novel selective T-cell depletion method may reduce graft-versus-host disease risk - Transfusion Medicine
Leukocyte depletion does not eradicate HTLV-1 - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
